Trial tests drug duo to fight tough brain cancer

NCT ID NCT03581942

Summary

This study tested a combination of two oral drugs, copanlisib and ibrutinib, for people with a rare and aggressive brain cancer called primary central nervous system lymphoma that had come back or stopped responding to other treatments. The main goals were to find a safe dose and see if the drug combination could shrink tumors. It involved 18 adults who had already received at least one prior treatment for their brain lymphoma.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.